Cardiovascular readmissions and excess costs following percutaneous coronary intervention in patients with chronic kidney disease: Data from a large multi-centre Australian registry

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2783-2790

  Ariyaratne, Thathya V ^a   Ademi, Zanfina ^a,b   Duffy, Stephen J ^a,c   Andrianopoulos, Nick ^a   Billah, Baki ^a   Brennan, Angela L ^a   New, Gishel ^d   Black, Alexander ^e   Ajani, Andrew E ^f   Clark, David J ^g   Yan, Bryan P ^h   Yap, Cheng Hon ^a,e   Reid, Christopher M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d BOX HILL HOSPITAL   (Australia)

^e GEELONG HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g AUSTIN HOSPITAL   (Australia)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic kidney disease; Follow up costs; Health care costs; Health outcomes; Hospitalisation; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; SPIRONOLACTONE; WARFARIN;

ADULT; AUSTRALIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG UTILIZATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEART FAILURE; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; UNSTABLE ANGINA PECTORIS; AGED; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; COST; ECONOMICS; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE COMPLICATIONS; REGISTER; STATISTICS AND NUMERICAL DATA;

AGED; AUSTRALIA; CARDIOVASCULAR DISEASES; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84885642279     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.03.128     Document Type: Conference Paper

References (48)

1. Kidney Health Australia Chronic kidney disease (CKD) management in general practice 2nd ed. 2012 [Available online at: http://www.kidney.org.au/ LinkClick.aspx?fileticket=sMKP3HBuquM%3d&tabid=635&mid=1584. Accessed February 1, 2012]
2. A.C. Schoolwerth, M.M. Engelgau, and T.H. Hostetter Chronic kidney disease: a public health problem that needs a public health action plan Prev Chronic Dis 3 2006 A57
3. R.A. Hamer, and A.M. El Nahas The burden of chronic kidney disease BMJ 332 2006 563 564
4. A. Cass The economic impact of end-stage kidney disease in australia: projections to 2020 Available online at: http://www.kidney.org.au/LinkClick. aspx?fileticket=i759hVXpJI0%3D&tabid=635&mid=1837 2010 [Accessed February 5, 2011]
5. O.E. Ayodele, and C.O. Alebiosu Burden of chronic kidney disease: an international perspective Adv Chronic Kidney Dis 17 2010 215 224
6. A. Meguid El Nahas, and A.K. Bello Chronic kidney disease: the global challenge Lancet 365 2005 331 340
7. R. Vanholder, Z. Massy, and A. Argiles Chronic kidney disease as cause of cardiovascular morbidity and mortality Nephrol Dial Transplant 20 2005 1048 1056
8. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease Circulation 108 2003 2154 2169
9. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.-Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
10. S.E. Baumeister, C.A. Boger, and B.K. Kramer Effect of chronic kidney disease and comorbid conditions on health care costs: a 10-year observational study in a general population Am J Nephrol 31 2010 222 229
11. F.G. Hage, R. Venkataraman, G.J. Zoghbi, G.J. Perry, A.M. DeMattos, and A.E. Iskandrian The scope of coronary heart disease in patients with chronic kidney disease J Am Coll Cardiol 53 2009 2129 2140
12. D.N. Reddan, L.A. Szczech, and R.H. Tuttle Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease J Am Soc Nephrol 14 2003 2373 2380
13. J.H. Ix, N. Mercado, and M.G. Shlipak Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS) Am Heart J 149 2005 512 519
14. F. Latif, N.S. Kleiman, and D.J. Cohen In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry JACC Cardiovasc Interv 2 2009 37 45
15. E. Nikolsky, R. Mehran, and D. Turcot Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention Am J Cardiol 94 2004 300 305
16. J.A. Shaw, N. Andrianopoulos, and S. Duffy Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents Cardiovasc Revasc Med 9 2008 218 223
17. A. Meyer, H. Bunzemeier, and M. Hausberg Impact of different stages of chronic kidney disease on in-hospital costs in patients with coronary heart disease Nephrol Dial Transplant 23 2008 1955 1960
18. M. Pohlen, H. Bunzemeier, W. Husemann, N. Roeder, G. Breithardt, and H. Reinecke Risk predictors for adverse outcomes after percutaneous coronary interventions and their related costs Clin Res Cardiol 97 2008 441 448
19. A.E. Ajani, G. Szto, and S.J. Duffy The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project Heart Lung Circ 15 2006 44 47
20. B.P. Yan, A.E. Ajani, and S.J. Duffy Use of drug-eluting stents in Victorian public hospitals Med J Aust 185 2006 363 367
21. W. Chan, D.J. Clark, and A.E. Ajani Progress towards a National Cardiac Procedure Database - development of the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and Melbourne Interventional Group (MIG) registries Heart Lung Circ 20 2011 10 18
22. N. Andrianopoulos, D. Dinh, and S.J. Duffy Quality control activities associated with registries in interventional cardiology and surgery Heart Lung Circ 20 2011 180 186
23. B. Lagerqvist, S.K. James, U. Stenestrand, J. Lindbäck, T. Nilsson, and L. Wallentin Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019
24. A.S. Levey, J. Coresh, and E. Balk National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
25. Australian Government, and Australian Refined Diagnostic Related Groups (AR-DRG) Available online at: http://www.health.gov.au/internet/main/publishing. nsf/content/health-casemix-ardrg1.htm 2011 [Accessed November 1, 2011]
26. S. Senes, and E. Penm Australian Institute of Health and Welfare. Medicines for cardiovascular health: are they used appropriately? Cardiovascular disease series no. 27. Cat. no. 36 2007 AIHW Canberra
27. Australian Government, Australian Department of Health and Ageing The Australian health care system - an outline Available online at: http://www.health.gov.au/internet/main/publishing.nsf/content/ eba6536e92a7d2d2ca256f9d007d8066/$file/ozhealth.Pdf [Accessed January 22, 2013]
28. M.K. Chapko, C.F. Liu, M. Perkins, Y.F. Li, J.C. Fortney, and M.L. Maciejewski Equivalence of two healthcare costing methods: bottom-up and top-down Health Econ 18 2009 1188 1201
29. Australian Government, Department of Health and Ageing Health Expenditure Australia 2008-09 Available online at: http://www.healthissuescentre.org.au/ documents/items/2010/12/357534-upload-00001.pdf 2010 [Accessed February 9, 2012]
30. Z. Ademi, H.L. Walls, and A. Peeters Economic implications of obesity among people with atherothrombotic disease Int J Obes 34 2010 1284 1292
31. Z. Ademi, D. Liew, and B. Hollingsworth The economic implications of treating atherothrombotic disease in Australia, from the government perspective Clin Ther 32 2010 119 132
32. Australian Government Pharmaceutical Benefits Scheme (PBS): medicine listing Available online at: http://www.pbs.gov.au/browse/medicine-listing 2012 [Accessed February 24, 2012]
33. Australian Government Pharmaceutical benefits schedule item reports 2012 [Available online at: https://www.medicareaustralia.gov.au/statistics/pbs-item. shtml. Accessed February 24, 2012]
34. Z. Ademi, C.M. Reid, and B. Hollingsworth Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH registry Clin Ther 33 2011 1456 1465
35. National Heart Foundation of Australia, and the Cardiac Society of Australia and New Zealand Reducing risk in heart disease Available from: http://www.heartfoundation.org.au/SiteCollectionDocuments/Reduce-risk-in-heart- disease-guideline.pdf 2007 [Accessed: March 1, 2012]
36. Australian Government Therapeutic goods administration. Product information & consumer medicines information search facility Available online at: http://www.tga.gov.au/hp/information-medicines-pi.htm 2012 [Accessed March 1, 2012]
37. A. Ahmed, and R.C. Campbell Epidemiology of chronic kidney disease in heart failure Heart Fail Clin 4 2008 387 399
38. S. Kar, W. Coats, and K. Aggarwal Percutaneous coronary intervention versus coronary artery bypass graft in chronic kidney disease: optimal treatment options Hemodial Int 15 2011 S30 S36
39. P.J. Best, R. Lennon, and H.H. Ting The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions J Am Coll Cardiol 39 2002 1113 1119
40. A.C. Schoolwerth, D.A. Sica, B.J. Ballermann, and C.S. Wilcox Renal considerations in angiotensin converting enzyme inhibitor therapy Circulation 104 2001 1985 1991
41. T.T. Tsai, J.C. Messenger, and J.M. Brennan Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry - CMS Claims Database J Am Coll Cardiol 58 2011 1859 1869
42. A.S. Levey, L.A. Stevens, and C.H. Schmid A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
43. Casemix view http://www.sma.org.sg/sma-news/3202/report.pdf [Accessed March 20, 2011]
44. Z. Ademi, D. Liew, B. Hollingsworth, P.G. Steg, D.L. Bhatt, C.M. Reid Investigators of REACH Registry Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry Am J Cardiovasc Drugs 10 2010 85 94
45. S.D. Barnett, A.M. Speir, and N. Ad Using the EuroSCORE to predict institution costs and identify patients at higher risk for resource consumption following open heart surgery Chest J 132 2007 440
46. D. Dinh, A.E. Newcomb, M. Huq, D.A. Reid, and H. Rizzoli Ausscore relates to cost of isolated CABG surgery Heart Lung Circ 20 2011 263
47. SYNTAX Investigators. Health related quality of life and U.S. economic outcomes of PCI with drug-eluting stents vs. bypass surgery: 1-year results from the SYNTAX trial. Available online at: www.theheart.org/displayItem.do? primaryKey=959203&type=ppt. Accessed November 22, 2012.
48. D.A. Savitz Interpreting epidemiologic evidence 2003 Oxford University Press New York, NY